Bacteriophage ΦCJ7 Antibacterial Composition for Salmonella Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods are ineffective in controlling Salmonella Enteritidis, Salmonella Typhimurium, Salmonella Gallinarum, and Salmonella Pullorum infections due to antibiotic resistance and lack of specific bactericidal agents, leading to significant economic and health issues in livestock and humans.
Innovation Solution
A novel bacteriophage, ΦCJ7, with specific bactericidal activity against these Salmonella strains, exhibiting acid- and heat-resistance, and desiccation tolerance, is developed for use in feed additives, drinking water, and sanitizers to prevent and treat infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibiotics are used to control Salmonella infections, then bacterial growth is inhibited, but antibiotic resistance develops
Solution Approach 1:
The patent employs bacteriophage ΦCJ7 as an intermediary agent to control Salmonella bacteria. Instead of using conventional antibiotics that directly target bacterial cell walls or metabolic pathways (causing resistance), the bacteriophage acts as a biological mediator that specifically infects and lyses Salmonella cells through viral replication cycles. This intermediary approach eliminates the resistance problem because the phage targets specific bacterial surface receptors and replicates inside the bacteria, a mechanism that does not induce antibiotic-style resistance.
Solution Approach 2:
The patent replaces the chemical mechanism of antibiotics with a biological mechanism of bacteriophage infection. Conventional antibiotics use chemical substances to inhibit bacterial growth, but the patent substitutes this with a living viral agent (bacteriophage ΦCJ7) that naturally infects and destroys Salmonella bacteria. This substitution transitions from a chemical-based antibacterial system to a biological-based system, achieving Salmonella control without the side effects of antibiotic resistance.
2Reliability
If broad-spectrum antibacterial agents are used, then bacterial infections are treated, but beneficial bacteria are also killed
Solution Approach 1:
The patent applies the principle of local quality through the high host specificity of bacteriophage ΦCJ7. The bacteriophage is designed to recognize and infect only specific Salmonella serotypes (such as Salmonella Enteritidis, Salmonella Typhimurium, Salmonella Gallinarum, and Salmonella Pullorum) by binding to unique surface receptors on these pathogens. This localized targeting ensures that beneficial bacteria in the gut microbiota remain unaffected, as the phage does not recognize or bind to their cell surfaces. The specificity is achieved through the phage's tail fiber proteins that match complementary receptors on Salmonella cells only.
3Reliability
If live attenuated vaccines are used for Fowl Typhoid prevention, then immunity is provided, but egg-transmitted infections occur
Solution Approach 1:
The patent extracts the protective function from the live attenuated vaccine and separates it from the harmful replication capability. Instead of using a live (even attenuated) Salmonella vaccine that can still replicate and potentially transmit to eggs, the patent uses bacteriophage ΦCJ7 which provides protection through competitive exclusion and direct lysis of pathogenic Salmonella. The phage can be administered as a spray, feed additive, or water supplement, providing protective immunity without the risk of vertical transmission to eggs, thus extracting the beneficial protection while removing the harmful transmission risk.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
ΦCJ7 effectively controls Salmonella populations in livestock and humans, reducing disease incidence and food safety risks without inducing antibiotic resistance, demonstrating its potential as a safe and effective alternative to conventional antibiotics.
Implementation Method 1
A novel bacteriophage, ΦCJ7, with specific bactericidal activity against these Salmonella strains
Implementation Method 2
exhibiting acid- and heat-resistance
Implementation Method 3
exhibiting acid- and heat-resistance
Implementation Method 4
desiccation tolerance
Data Source
Figure 1
Figure 2A~2H
Figure 3
AI summary
Disclosed herein are is a novel bacteriophage which has specific bactericidal activity against one or more Salmonella bacteria selected from the group consisting of Salmonella Enteritidis, Salmonella Typhimurium, Salmonella Gallinarum, and Salmonella Pullorum without affecting beneficial bacteria. Disclosed are also compositions, animal feeds or drinking water, cleaners and sanitizers for preventing and treating the infectious diseases caused by Salmonella Enteritidis, Salmonella Typhimurium, Salmonella Gallinarum or Salmonella Pullorum including salmonellosis, Salmonella food poisoning, Fowl Typhoid, and Pullorum disease or for controlling the salmonella bacteria.